GHK-Cu
GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper) is a naturally occurring tripeptide-copper complex originally discovered in human plasma, serum, and urine. This bioactive compound represents one of the most extensively studied and clinically validated peptides in regenerative medicine, demonstrating remarkable therapeutic properties through its multifaceted mechanisms of action including collagen synthesis stimulation, anti-inflammatory effects, antioxidant activity, and tissue remodeling enhancement.
This peptide has gained considerable attention in dermatology and aesthetic medicine for its studied role in wound healing, skin regeneration, hair follicle stimulation, and anti-aging applications. GHK-Cu exhibits unique stability as a copper chelate complex and maintains bioactivity across various physiological conditions, making it distinctive among therapeutic peptides with decades of clinical use and research validation.
Overview
GHK-Cu exists as a stable coordination complex where the copper ion is chelated by the histidine and terminal amino group, creating a distinctive blue-colored solution. The peptide demonstrates superior stability and biological activity compared to either component alone, and is metabolized through gradual peptide degradation with copper redistribution to tissue stores, with detectability up to 12 hours post-administration using standard analytical methods.
Chemical structure & Properties
- Molecular Formula: C14H24CuN6O4
- Molecular Formula (copper-free): C14H24N6O4
- Molecular Weight: 403.93 Da (with copper), 340.38 Da (without copper)
- Sequence: Glycyl-L-Histidyl-L-Lysine complexed with Cu²⁺
- Half-life: 2-4 hours (plasma circulation)
- Stability: Stable copper chelate complex with enhanced bioavailability
Mechanism of Action
GHK-Cu exerts its therapeutic effects through multiple interconnected molecular pathways:
Areas Investigated in
the Research Literature
Current Clinical Evidence
Safety Profile and Considerations
Regulatory Status and Legal Considerations
Regulatory information current as of 28 August 2026. This is a summary, not legal or medical advice, and status can change.
FDA Status
- Classification: Varies by administration route and concentration
- Topical Applications: Available in cosmetic and cosmeceutical formulations
- Injectable Forms: Previously listed as Category 2 for injectable routes. Nominated but withdrawn as of April 22, 2026. Removal from Category 2 does not authorize compounding of injectable GHK-Cu — it is not on the FDA's 503A bulk drug substances list, so no lawful compounding pathway currently exists.
- Regulatory Position: Research use available for investigational applications
WADA Status
- Classification: Not specifically prohibited in current regulations
- Athletic Use: Generally permitted in topical applications
- Testing: Limited detection methods for performance monitoring
Legal Availability
- Commercial Status: Present in cosmetic topical products. Not FDA approved as a medicine.
- Market Presence: Concentrations from 0.1% to 2% in cosmetic products
- Quality Control: Wide variation in product quality and concentration accuracy
- Clinical Use: Professional supervision recommended for therapeutic applications
Conclusion
What the evidence supports
GHK-Cu is a copper-binding peptide studied in cell-culture and animal models for effects on collagen synthesis, wound healing and tissue remodeling, with a long history of use in topical cosmetic formulations. Evidence for injectable therapeutic use is limited, human trials are small, and long-term safety for that route has not been established. GHK-Cu is available in topical cosmetic products, but injectable GHK-Cu is not FDA approved and is not on the FDA's 503A bulk drug substances list, so no lawful compounding pathway currently exists for it. This page summarizes the published research and nothing further.
GHK-Cu SCIENTIFIC
DATA SUMMARY
About this library
This library is published for education. It summarizes published research on compounds studied in this field. Many have no approved medical use, and several cannot lawfully be compounded in the United States. The presence of a page here does not mean Paragon offers that compound. Nothing on these pages is an offer to treat.
This page is general education about a compound studied in this field. Nothing here is medical advice, a recommendation, or an offer to prescribe or supply. A page appearing in this library does not mean Paragon Sports Medicine offers that compound.
Disclaimer: This information is provided for educational purposes only and does not constitute medical advice. GHK-Cu availability and regulatory status vary by jurisdiction and administration route. Injectable forms were previously listed as Category 2. As of April 22, 2026 that classification has been changed to Nominated but Withdrawn. Removal from Category 2 does not authorize compounding; injectable GHK-Cu is not on the 503A bulks list. Patients should consult with qualified healthcare providers before considering any peptide therapy.
Statements on this page have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Many peptides described here are not FDA approved for the uses discussed, and some cannot lawfully be compounded in the United States. Nothing on this page is medical advice or a recommendation for any individual. Whether any therapy is appropriate depends on your history, your laboratory results, and a clinical evaluation. Individual results vary. This page is published for education. Use of this site does not create a physician-patient relationship.